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Abstract
Chronic kidney disease (CKD) is a worldwide public health problem that is associated with substantial morbidity and 
mortality. To search for sequence variants that associate with CKD, we conducted a genome-wide association study 
(GWAS) that included a total of 3,203 Icelandic cases and 38,782 controls. We observed an association between CKD and 
a variant with 80% population frequency, rs4293393-T, positioned next to the UMOD gene (GeneID: 7369) on 
chromosome 16p12 (OR=1.25, P = 4.1 x10_10). This gene encodes uromodulin (Tamm-Horsfall protein), the most 
abundant protein in mammalian urine. The variant also associates significantly with serum creatinine concentration 
(SCr) in Icelandic subjects (N = 24,635, P = 1.3x10_23) but not in a smaller set of healthy Dutch controls (N = 1,819, 
P = 0.39). Our findings validate the association between the UMOD variant and both CKD and SCr recently discovered in 
a large GWAS. In the Icelandic dataset, we demonstrate that the effect on SCr increases substantially with both age 
(P = 3.0x10_17) and number of comorbid diseases (P = 0.008). The association with CKD is also stronger in the older age 
groups. These results suggest that the UMOD variant may influence the adaptation of the kidney to age-related risk 
factors of kidney disease such as hypertension and diabetes. The variant also associates with serum urea (P = 1.0x10_6), 
uric acid (P = 0.0064), and suggestively with gout. In contrast to CKD, the UMOD variant confers protection against 
kidney stones when studied in 3,617 Icelandic and Dutch kidney stone cases and 43,201 controls (OR = 0.88, 
P = 5.7x10"5).
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Introduction
Chronic kidney disease (C K D ) is a common disorder that can 
progress to kidney failure and is associated with an increased risk 
of cardiovascular disease and m ortality [1,2]. The cause of C K D  is 
not always known and frequently appears multifactorial with 
hypertension (H T N ) and diabetes mellitus (DM ) being the most 
important causes [3-6]. O ther causes include intrinsic kidney 
disorders, atherosclerosis and nephrotoxic drugs [7,8]. Studies also 
indicate a dramatic increase in the prevalence of C K D  with 
advancing age [9,10]. W ith  greater lifespan, the burden of C K D  is 
thus steadily rising in the Western world [11], resulting in a 
substantial impact on the health care system [12].
Previous studies have suggested a genetic contribution to the 
risk of kidney disease. Heritability estimates of serum creatinine 
(SCr) and estimated glomerular filtration rate based on SC r 
(eGFRcrea), both common measures of kidney function, have 
been reported as 29% and 33%, respectively [13]. Recently, 
Kottgen et al. [14] published the first genome-wide association 
study (G W A S) on eGFRcrea, eG FR  based on cystatin C 
(eGFRcys), another measure of kidney function, and C K D , 
reporting significant association with eG FRcrea at three loci 
(UMOD, SHROOM3 (GeneID : 57619) and GATM-SPATA5L1 
(GenelDs: 2628 and 79029)), w ith eGFRcys at two loci (CST3- 
CST9 (GenelDs: 1471 and 128822) and STC1 (GeneID : 6781)) 
and with C K D  at one locus (UMOD) [14].
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Chronic kidney disease (CKD) is a common condition that 
is associated with substantial morbidity and mortality and 
has been recognized as a major public health problem 
worldwide. Common causes of CKD include hypertension, 
diabetes, and inflammatory disorders. Previous studies 
have shown a significant genetic contribution to kidney 
disease and a recent genome-wide association study 
yielded a variant in the UMOD gene that affects the risk 
of CKD. Here, we replicate the association between UMOD 
and CKD in an independent analysis. We also demonstrate 
for the first time an interaction between the UMOD variant 
and age that suggests that this variant may adversely 
affect the aging kidney and its adaptation to age-related 
risk factors of kidney disease, such as hypertension and 
diabetes. Furthermore, we show that the UMOD variant 
that affects risk of CKD also provides protection against 
kidney stone disease.
Author Summary
W ith  the aim of discovering sequence variants that associate 
with kidney function, we conducted a G W A S in a total of 3,203 
Icelanders with C K D  and 38,782 controls and in 24,635 Icelandic 
and 1,819 Dutch subjects with SC r information. W e found a 
sequence variant at the UMOD locus that associates with both 
C K D  and SC r at a genome wide-significant (G W S) level, 
providing an independent replication of the result by Kottgen et 
al [14]. W e also show that this variant interacts with age-related 
increase in SC r levels with little or no effect on SC r before the age 
of 50 years, followed by a rapidly growing effect with increasing 
age. W e demonstrate that this variant associates significantly with 
serum urea, uric acid and suggestively with gout. In  contrast to the 
deleterious effect on kidney function, the variant confers protection 
against kidney stone disease.
Results/Discussion
Genome-wide association of variants at the UMOD locus 
with CKD and SCr
A  G W A S of 2.5 m illion SNPs, either directly genotyped 
(Illum ina HumanHap300 or Hum anHapCNV370 bead chips) or 
imputed based on the HapM ap C E U  samples [15], was performed 
on a sample set of 2,903 Icelanders with C K D  (see Materials and 
Methods for sample set description) and 35,818 controls and also
on 22,256 Icelandic subjects with SC r information (See QQ-plots 
in Figure S1 and Figure S2). The Icelandic SC r measurements 
came from two laboratories; the Laboratory in Mjodd, a private 
outpatient laboratory, and the C linical Biochemistry Laboratory of 
Landspitali University Hospital (LU H ), serving both inpatients 
and outpatients. These subjects had 5.2 SC r measurements on 
average (geometric mean) and we used the median SC r value for 
each individual in the subsequent analysis. The SC r values from 
the two Icelandic laboratories showed similar dependence on age 
and sex but there was clearly a trend towards higher SC r in the 
hospital laboratory compared with the outpatient laboratory 
(Figure S3).
The G W A S on C K D  and SC r both yielded several SNPs in 
high linkage disequilbrium (LD ) on chromosome 16p12 with G W S 
(P< 5x10_8) association to increased risk of C K D  and elevated 
SC r. For both phenotypes, this signal is tagged by rs4293393-T 
(Table 1 and Table 2). For C K D , the odds ratio (O R ) conferred by 
rs4293393-T was 1.25 (95% C I = 1.16-1.34) with a corresponding 
P  value of 6.2x10 9. In  an attempt to replicate this finding, 
rs4293393 was typed in additional 300 Icelandic subjects with 
C K D  and 2,964 controls. The association was nominally 
significant in the replication sample set and the effect size 
consistent with the initial observation (Table 1). The combined 
O R  for rs4293393-T in the two Icelandic C K D  sample sets was 
1.25 (95% C I = 1.17-1.35) and P  =4.1x10 10. The association 
between SC r and rs4293393-T on 16p12 was very strong with an 
effect of 1.86 mmol/L per allele carried and P  =6.7x10 20 
(Table 2). To follow up on these results, we genotyped 
rs4293393 in 2,379 additional Icelanders with SC r information, 
significantly replicating the initially observed effect (P  = 1.4x10 5, 
Table 2). Analysis of the combined Icelandic datasets showed a 
strong G W S  association between rs4293393-T and elevated SC r 
(effect = 1.93 mmol/L per allele, 95% C I=  1.55-2.31 mmol/L; 
P = 1.3x10 23). O ur findings provide an independent replication 
of the recently reported results by Kottgen et al [14] of an 
association of this 16p12 locus with C K D  and eGFRcrea. The 
strongest SN P  associations outside the UMOD region on 
chromosome 16p12 are shown in Table S1 (for C K D ) and Table 
S2 (for SC r), respectively.
For further assessment, we tested rs4293393 in 1,819 Dutch 
subjects with SC r information. These were healthy population- 
based controls (see Materials and Methods for sample set 
description) with SC r values substantially different from the 
Icelandic measurements, generally showing lower values and
Table 1. Association of rs4293393-T with chronic kidney disease (CKD).
CKD N Frequency
population case control case control OR (95%  CI) P
Icelandic discovery 2,903 35,818 0.831 0.798 1.25 (1.16, 1.34) 6.2x10 “  9
Icelandic replication 300 2,964 0.840 0.798 1.33 (1.05, 1.68) 0.019
Icelandic combined 3,203 38,782 0.832 0.798 1.25 (1.17, 1.35) 4.1 x10 “  10
YOB$1950 143 38,782 0.811 0.798 1.09 (0.81, 1.46) 0.57
1950. YOB$ 1940 355 38,782 0.821 0.798 1.16 (0.96, 1.41) 0.12
1940. YOB$ 1930 1,029 38,782 0.834 0.798 1.28 (1.14, 1.43) 3.1*10 “  5
1930. YOB$ 1920 1,242 38,782 0.838 0.798 1.31 (1.18, 1.46) 4.1*10 “  7
1920. YOB 434 38,782 0.825 0.798 1.19 (1.00, 1.42) 0.045
Association of rs4293393-T with CKD in Icelandic subjects. Association is shown for the discovery sample set, the replication sample set, the combined Icelandic sample, 
and finally, for the combined sample stratified by year of birth (YOB) as a proxy for age at onset. 
doi:10.1371/journal.pgen.1001039.t001
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Table 2. Association of rs4293393-T with serum creatinine
concentration (SCr).
SCr sample N Effect (95%  CI) P
Icelandic discovery 22,256 1.86 (1.46, 2.25) 6.7x10 - 20
Icelandic replication 2,379 2.68 (1.47, 3.89) 1.4x10 - 5
Icelandic combined 24,635 1.93 (1.55, 2.31) 1.3x10 - 23
Dutch replication 1,819 0.38 ( -  0.48, 1.25) 0.39
Association of rs4293393-T with SCr in Icelandic and Dutch subjects. Association is 
shown for the discovery sample set, the Icelandic and Dutch replication sample 
sets and the combined Icelandic sample. The population frequency of rs4293393-T 
is 0.80 in Iceland and 0.81 in the Netherlands. Effects are given in mmol/L. 
doi:10.1371/journal.pgen.1001039.t002
much less variability (Figure S3). Interestingly, no association was 
observed in the 1,819 healthy Dutch subjects (effect = 0.38 mmol/ 
L , 9 5 % C I=  — 0.48-1.25 mmol/L; P  =0.39) (Table 2). Significant 
heterogeneity was observed between the SC r association results for 
the Icelandic and Dutch populations (I2 = 90.4%, P  = 0.0013).
The SN P  rs4293393 is located 550 basepairs upstream of 
UMOD, encoding uromodulin, also known as the Tamm-Horsfall 
protein (Figure 1). The protein is a glycosylphosphatidylinositol 
(GPI)-anchored glycoprotein, exclusively expressed in the thick 
ascending loop of Henle [16] and distal convoluted tubule [17] of 
the mammalian kidney. It  is the most abundant protein in urine of 
healthy individuals, where it is present in a highly aggregated state 
[18,19]. W hile the exact physiological function of uromodulin 
remains to be elucidated, it has the capacity to bind to a variety of
ligands. It  has been reported to prevent bacteria from adhering to 
human kidney cells [20] and to inhibit calcium oxalate 
crystallization [21]. It  may also have a role in ion transport and 
immunological processes [22,23]. UMOD knockout mice have 
been shown to have decreased creatinine clearance [24] and 
predilection for both urinary tract infections [25] and calcium 
oxalate stone formation [26].
The rs4293393 variant is in perfect LD  in the HapM ap C E U  
samples [15] with a synonymous SN P  in UMOD, rs13335818, 
coding for V264V (D ' = 1.0, r2 = 1.0). The same perfect correla­
tion between rs4293393 and rs13335818 was observed in a set of 
3,364 Icelanders (D ' = 1.0, r2=1.0). Both rs4293393 and 
rs13335818 are also in perfect correlation with rs12917707 
(D ' = 1.0, r2 = 1.0 for both markers in the HapM ap C E U  samples 
[15]) near the UMOD, the variant reported by Kottgen et al [14] 
to associate with both C K D  and eG FRcrea with similar effect, 
indicating that these SN Ps are tagging the same signal. As 
rs4293393 is on the Illum ina 300/370K chips we used for direct 
genotyping, we refer to rs4293393 in the remainder of this article.
The effect of the UMOD variant on SCr is age-dependent
Given that SC r varies substantially with both age and sex, we 
tested for an interaction between the effect of rs4293393-T and 
effects of age and sex on SC r. No interaction was found between 
the UMOD variant and sex (P  =0.41). In  contrast, a strong 
interaction was observed between the UMOD variant and age in 
the Icelandic sample set (P  =3.0x10 ). On average, SC r 
increased by an additional 0.09 mmol/L per year per allele of 
rs4293393-T (95% C I = 0.07-0.11). In  order to visualize this 
interaction, we stratified our Icelandic samples based on age and
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Figure 1. An overview of the region around rs4293393. Shown are the -  log10 association P values of SNPs in the region with CKD (black 
circles), the SNPs' build 36 coordinates, the genes in the region and their exons (in blue), and recombination rates in centimorgans (cM) per 
megabase (Mb) (pink histogram). 
doi:10.1371/journal.pgen.1001039.g001
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sex and tested for association within each stratum (Figure 2A). 
Interestingly, rs4293393-T has little or no effect on SC r before the 
age of 50 years, but thereafter the effect increases rapidly with 
advancing age, especially around 70 years. Thus, the variant does 
not affect SC r in young individuals but rather how SC r increases 
with age. W e note that due to the relatively short time span in 
which the SC r data were collected there is an inherent 
confounding between age and generation in our study, which w ill 
require further investigation to resolve. Sim ilar interaction 
between the UMOD variant, age and C K D  was also observed 
when the association analysis for C K D  was stratified by year of 
birth used here as a proxy for age of onset (Table 1).
Although it is well known that kidney function declines with age, 
G F R  has been shown to decrease more slowly with senescence in 
healthy individuals than previously thought [3-5,11]. Comorbid 
conditions that increase in frequency with aging, including H T N , 
D M , atherosclerosis and heart failure are, however, increasingly 
recognized as important contributors of age-related decline in kidney 
function [3,4,6-8]. W e thus proceeded to investigate whether the age 
effect observed in carriers of the UMOD variant is influenced by 
interaction with age-related risk factors for decline in kidney function.
UMOD-associated increase in SCr with age is affected by 
the number of comorbid conditions present
As H T N , type 2 D M  and atherosclerosis are all well recognized 
age-dependent risk factors for C K D  [3,4,6-8], the association 
analysis was repeated after stratifying the SC r data based on these 
conditions. Incomplete information regarding history of H T N  
(5,705 cases), type 2 D M  (1,422 cases) and myocardial infarction 
(M I, 2,551 cases) was available for the Icelandic SC r sample set. In  
parallel w ith previous studies, the rate of increase in SC r with age 
was significantly higher in individuals with H T N  than in 
individuals without this diagnosis (effect = 0.23 mmol/L/year, 
95% C I = 0.19-0.26 mmol/L/year; P  =2.9x10—35). Sim ilar re­
sults were obtained for type 2 D M  (effect = 0.26 mmol/L/year, 
95% C I = 0.19-0.34 mmol/L/year; P  =1.1x10—n ) and M I (ef­
fect =0.36 mmol/L/year, 95% C I = 0.30-0.42 mmol/L/year; 
P  = 1.4x10 32) as well as the number of comorbid conditions 
(Figure 2B). W e also found that the effect of rs4293393-T on SC r 
increases with the number of comorbid conditions present 
(Figure 2C).
To further assess the relationship between genotype, age and 
risk factors for reduced kidney function, we investigated the effect 
of the rs4293393-T allele count on the increase in SC r with age 
stratifying on H T N  and type 2 D M . A  trend was observed for a 
higher rate of increase in SC r with age and rs4293393-T allele 
count in individuals with H T N  compared to those without a 
diagnosis of H T N  (P  = 0.077) as well as in those with type 2 D M  
compared to those without (P  =0.063). In  other words, the age- 
related increase in SC r levels appears to be greater in rs4293393-T 
carriers that have either H T N  or type 2 D M  than in carriers who 
do not have these risk factors. However, an age effect was still 
observed after accounting for these age-related risk factors. 
Furthermore, we also observed a significantly higher rate of SC r 
increase with age and rs4293393-T allele count stratifying on the 
number of comorbid conditions present (P  = 0.0080) (Figure 2D).
To determine whether rs4293393-T influenced kidney function 
by directly affecting known risk factors, we tested the association of 
rs4293393-T in well powered Icelandic case-control sets of H T N , 
M I, stroke, and type 2 D M  (Table S3). A  weak nominally 
significant association of rs4293393-T with increased risk of H T N  
was observed (O R  = 1.07, 95% C I = 1.01-1.12; P  = 0.014), but not 
with the other diseases tested. These data demonstrate that the 
effect of rs4293393-T on kidney function is not mediated through
increased risk of these comorbid conditions, but rather suggest that 
the variant may affect the vulnerability of the kidney to these risk 
factors.
These findings, demonstrating not only the effect of age on 
UMOD-associated increase in SC r but also the effect of age-related 
comorbid conditions, may explain why no association was 
observed between rs4293393-T and kidney function in the Dutch 
sample set of healthy population-based subjects with much lower 
SC r values and of much less variability than observed in the 
Icelandic samples (Figure S3).
Association of the UMOD variant with serum urea
Urea is another small solute that is commonly used to assess 
renal function together with SC r. The correlation between SC r 
and serum urea in our data was 58%. W e tested for association 
between rs4293393-T and serum urea in an Icelandic sample set 
that had urea measurements performed at the Laboratory in 
M jodd (N  = 4,084) and found significant association with increased 
serum urea concentration (effect = 0.36 m g/dL, 95% C I = 0.23­
0.50 m g/dL; P  = 1.0x10—6).
Association of the UMOD variant with uric acid and gout
In  humans, rare mutations in the UMOD gene that cause 
accumulation of abnormal uromodulin in the nephron and 
reduced urinary excretion of the normal protein [27] have been 
associated with two autosomal dominant kidney diseases with 
overlapping clinical features, medullary cystic kidney disease and 
fam ilial juvenile hyperuricemic nephropathy [28]. These disorders 
are characterized by hyperuricemia, gout and progressive renal 
failure due to tubulointerstitial nephropathy. G iven the link 
between UMOD and hyperuricemia, we tested rs4293393-T in 
Icelandic subjects with serum uric acid values from the Laboratory 
in M jodd (N  = 6,583) and observed significant association 
(effect = 6.1, 95% C I=  1.7-10.4; P  =0.0064). W e then tested for 
association with gout in a set of 377 Icelandic cases and 39,916 
controls (see Materials and Methods for sample set description) 
and found a suggestive association (O R  =1.17, 95% C I = 0.97­
1.41; P  =0.097). These data contrast the work of Kottgen et al 
[14] that neither detected association with serum uric acid nor 
gout.
Reduced risk of kidney stone formation in carriers of the 
UMOD CKD risk variant
As uromodulin is thought to prevent the formation of calcium- 
containing kidney stones [21], we tested rs4293393 in a sample set 
of 1,689 Icelandic patients with radiopaque kidney stones and 
37,076 Icelandic population controls. W e observed a significant 
association between rs4293393-T and reduced risk of kidney 
stones (O R  = 0.88, 95% C I = 0.81-0.96; P  =0.0053). In  an 
attempt to replicate this observation, we genotyped rs4293393 in 
two additional sample sets of European ancestry, one from Iceland 
(1,271 cases and 3,177 controls) and the other from the 
Netherlands (701 cases and 2,948 controls) (Table 3). The effect 
size in both replication samples is consistent with the initial 
observation and the association is significant in the combined 
replication samples (O R  = 0.89, 95% C I = 0.81-0.97; P  = 0.0089). 
There was no correlation between the effect size and year of birth 
of the kidney stone patients (Table S4).
Replication of the SHROOM3 and GATM-SPATA5L1 
eGFRcrea loci and the STC1 and CST3-CST9 eGFRcys loci
Kottgen et al [14] reported on variants at additional loci with 
G W S  association to eG FRcrea (SHROOM3 and GATM-SPA-
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number of comorbid conditions and sex. (D) The interaction effect between age and rs4293393-T allele count on SCr stratified by the number of 
comorbid conditions and sex. The circles give the point estimates and the vertical lines show their 95% confidence intervals. Estimates and 
confidence intervals are given in blue for males and red for females. Sample sizes (N) are given for each strata for males and females, respectively. 
Effects are given in mmol/L in (A-C) and mmol/L/year in (D). 
doi:10.1371/journal.pgen.1001039.g002
TA5L1) or eGFRcys (STC1 and CST3-CST9). W e tested these 
variants in our Icelandic datasets, including a small sample set with 
cystatin C measurements (Table 4). The association with SC r 
replicated for both the SHROOM3 and GATM-SPATA5L1 SNPs 
(P  = 0.00057 and P  = 0.0067, respectively) and the association with 
cystatin C replicated for the CST3-CST9 SN P  but not the STC1 
SN P  (P  =0.00037 and P  =0.73, respectively). It  should be noted, 
however, that the Icelandic cystatin C sample set is very small 
(N  = 284) and possibly underpowered to replicate the reported 
association with the STC1 SN P. The STC1 SN P  did show 
association with SC r in our dataset (P  = 1.6-10 6) as was observed 
in the analysis by Kottgen et al [14]. The SHROOM3 and GATM- 
SPATA5L1 SN Ps showed suggestive association with C K D  in the 
analysis by Kottgen et al [14] and our data support this association 
but do not constitute a conclusive replication. In  contrast to the 
UMOD variant, we did not observe an interaction between the 
variants at these other loci and age. Furthermore, none of the 
SNPs did associate with kidney stones in Iceland (data not shown). 
Finally, Kottgen et al [14] reported suggestive association between 
eG FRcrea and variants at JAG1 (GeneID : 182); we did not 
replicate this finding in our SC r scan (for rs6040055-T: 
effect = — 0.27, 95% C I = — 0.60—0.05), P  =0.17).
In  summary, we describe sequence variants next to and in 
UMOD that associate with increased risk of C K D  and elevated 
SC r but confer protection against kidney stones. W e also 
demonstrate an interaction between these variants and both age 
and comorbid conditions that are related to decline in kidney 
function. O ur observations indicate that UMOD is important for 
maintaining kidney function with advancing age and exposure to 
risk factors that are associated with aging, such as H T N , type 2 
D M  and cardiovascular disease.
Materials and Methods
Study subjects from Iceland
Landspitali University Hospital (LU H ) is a regional hospital for 
the greater Reykjavik area and a tertiary referral center for the 
entire Icelandic nation. The population of Iceland is comprised of 
330,000 inhabitants of whom approximately 200,000 reside in the 
greater Reykjavik area. The nation’s only nephrology clinic is 
located at L U H  and all laboratory tests for the prim ary care clinics 
of the greater Reykjavik area are performed in the hospital’s
Table 3. Association of rs4293393-T with kidney stones.
laboratories. W e obtained results of all SC r measurements 
performed during the period 2003 to 2008 from the computerized 
database of the C linical Laboratories at L U H  and used the SC r 
values to identify those with chronic kidney disease (C K D ) based 
on calculation of the estimated glomerular filtration rate (eG FR) 
by the original 4-variable Modification of D iet in Renal Disease 
(M D R D ) study equation. W e classified those with eG FR< 60 ml/ 
min/1.73 m2 as having C K D . A ll individuals with acute kidney 
injury and those who had eG FR< 60 ml/min/1.73 m2oflessthan 
3 months duration were excluded from the C K D  sample set. The 
study included C K D  patients that had donated blood through 
various genetic programs at deC O D E genetics.
Biochem ical measurements including SCr, serum urea, serum 
uric acid and serum cystatin C were available from two 
laboratories, the Laboratory in M jodd, Reykjavik, Iceland, a 
private outpatient laboratory, and the C linical Biochemistry 
Laboratory of L U H , serving both inpatients and outpatients. 
The main referral center for the Laboratory in M jodd is a 
multispecialty medical clinic in Reykjavik (Laeknasetrid). The 
laboratory tests were done in the years 1997-2008 at the 
Laboratory in M jodd and in the years 2003-2008 at L U H . The 
Icelandic SC r measurements came from both laboratories, the 
Laboratory in M jodd (N  = 10,260) and L U H  (N  = 22,898, of 
whom 8,523 also had measurements from the Laboratory in 
Mjodd). A t the L U H , the same enzymatic method was used for 
measurement of SC r during the study period (Vitros 950 
Autoanalyzer, Ortho Clinical Diagnostics, Rochester, M N , 
U SA ), whereas at the Laboratory in M jodd, SC r measurements 
were performed by modified kinetic Jaffe rection assays until M ay 
2007 when an enzymatic method was introduced.
The Icelandic kidney stone cases consisted of patients with 
confirmed radiopaque kidney stones from the Icelandic Kidney 
Stone Disease Registry at L U H . The study included kidney stone 
patients that had donated blood through various genetic programs 
at deC O D E genetics.
The coronary artery disease [29], stroke [30] and type 2 D M  
[31,32] patient groups from Iceland have been described 
previously. The H T N  sample set includes individuals who have 
been recruited into various genetic programs at deC O D E and 
have: (1) self-reported H T N ; (2) received the diagnosis of H T N  at 
discharge from the L U H ; or (3) have attended the Hypertension 
C linic at L U H . The gout sample set includes subjects who were
Kidney stone N Frequency
population case control case control OR (95%  CI) P
Icelandic discovery 1,689 37,076 0.781 0.801 0.88 (0.81, 0.96) 0.0053
Icelandic replication 1,271 3,177 0.786 0.801 0.91 (0.81, 1.03) 0.13
Icelandic combined 2,916 40,253 0.782 0.801 0.89 (0.83, 0.95) 0.00075
Dutch replication 701 2,948 0.782 0.810 0.85 (0.73, 0.98) 0.022
Combined 3,617 43,201 - - 0.88 (0.83, 0.94) 5.7x10 - 5
Association of rs4293393-T with kidney stone disease in Icelandic and Dutch subjects. Association is shown for the discovery sample set, the Icelandic and Dutch 
replication sample sets, the combined Icelandic sample, and all the sample sets combined. 
doi:10.1371/journal.pgen.1001039.t003
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recruited into various genetic programs at deC O D E and reported 
the use of either one of two specific anti-gout medications, 
allopurinol or colchicine.
The Icelandic controls used in the case-control genome-wide 
association studies (G W A S) and replication studies were selected 
among individuals who had participated in the various genetic 
programs at deC O D E genetics; tremor, preeclampsia, endome­
triosis, psoriasis, type 2 D M , Alzheimer’s disease, osteoarthritis, 
schizophrenia, peripheral artery disease, abdominal aortic aneu­
rysm, chronic obstructive pulmonary disease, stroke, osteoporosis, 
coronary artery disease, H T N , asthma, Parkinson’s disease, sleep 
apnea, age-related macular degeneration, polycystic ovary syn­
drome, rheumatoid arthritis, lung cancer, longevity, benign 
prostatic hyperplasia, enuresis, migraine, glaucoma, attention 
deficit hyperactivity disorder, prostate cancer, infectious diseases, 
anxiety, expression studies, autism, dyslexia, melanoma, colorectal 
cancer, deep vein thrombosis, restless leg syndrome, studies on 
addiction and population controls. Individuals who reported a 
history of the trait being tested (e.g. C K D ) were excluded from the 
control set. Some of the controls participated in more than one 
genetic program in which case their genotypes are only included 
once.
The study was approved by the Icelandic Data Protection 
Authority and the National Bioethics Committee. A ll patients 
signed informed consent and donated blood samples. Personal 
identities of the patients and biological samples were encrypted by 
a third party system provided by the Icelandic Data Protection 
Authority.
Study subjects from The Netherlands
A ll samples with SC r measurements came from the Nijmegen 
Biom edical Study. The details of this study have been reported 
previously [33]. Briefly, this is a population-based survey 
conducted by the Department of Epidemiology and Biostatistics 
and the Department of C linical Chemistry of the Radboud 
University Nijmegen M edical Center (R U N M C ), in which 9,371 
individuals participated from a total of 22,500 age- and sex- 
stratified, randomly selected inhabitants ofNijm egen. The subjects 
were invited to participate in a study on gene-environment 
interactions in complex diseases. A ll participants filled out a 
questionnaire on lifestyle and medical history at baseline and 6500 
of them donated blood samples for D N A  isolation and 
biochemical studies. A  fraction of the study participants were 
previously genotyped with the Illum ina HumanHap300 or 
Hum anHapCNV370 bead chips; these were selected to serve as 
controls in G W A S on prostate and breast cancer and were selected 
prim arily based on age. A  total of 1,819 individuals had both 
serum creatinine measurements and genome-wide SN P  data 
available for analysis in this study.
The Dutch patients with kidney stones were recruited from two 
sources: The outpatient clinics of the R U N M C  and The Nijmegen 
Biom edical Study. A ll patients who present to the outpatient 
clinics of the R U N M C  are invited to participate in a study on the 
effects of genes and lifestyle on the development of urological 
diseases. In  case of consent, the patients fill out a questionnaire on 
lifestyle and donate a blood sample for D N A  isolation. The 
controls for the analysis of kidney stone disease were also taken 
from the biobank of the Nijmegen Biom edical Study. A ll patients 
and controls were of self-reported European descent and were fully 
informed about the goals and the procedures of these studies. The 
study protocols for the recruitment of patients from outpatient 
clinics and the recruitment of participants to the Nijmegen 
Biom edical Study were approved by the R U N M C  Institutional 
Review  Board. A ll study subjects gave written informed consent.
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Illumina genome-wide genotyping
A ll Icelandic case and control samples were assayed with the 
Illum ina HumanHap300 or Hum anHapCNV370 bead chips 
(Illum ina, SanDiego, CA, U SA ), containing 317,503 and 
370,404 haplotype tagging SN Ps derived from phase I  of the 
International HapM ap project, respectively. O nly SN Ps present 
on both chips were included in the analysis and SNPs were 
excluded if they had: (a) yield lower than 95% in cases or controls; 
(b) minor allele frequency less than 1% in the population; or (c) 
showed significant deviation from Hardy-Weinberg equilibrium in 
the controls (P<0.001). Any samples with a call rate below 98% 
were excluded from the analysis. The final analysis included 
302,379 SNPs.
Imputation of SNP genotypes
The genome-wide association scan was based on expected allele 
counts obtained with the IM P U T E  software [34], using the HapM ap 
C E U  samples as a training set [15]. The test for association was then 
performed using the expected allele counts as covariates. The 
imputation information was estimated by the ratio of the observed 
likelihood of allele counts and the likelihood of allele counts assuming 
perfect information under the assumption of Hardy-Weinberg 
equilibrium. The estimated information for the four SNPs imputed 
in Table 4 was high in all instances (>0.96).
Single SNP genotyping
Single SN P  genotyping of all samples was carried out at 
deC O D E genetics in Reykjavik, Iceland, applying the same 
platform to all populations studied. A ll single SN P  genotyping was 
carried out using the Centaurus (Nanogen) platform [35]. The 
quality of each Centaurus SN P  assay was evaluated by genotyping 
each assay on the C E U  samples and comparing the results with 
the HapM ap data. A ll assays had a mismatch rate < 0.5%. 
Additionally, all markers were re-genotyped on more than 10% of 
samples typed with the Illum ina platform resulting in an observed 
mismatch in less than < 0.5% of samples.
Association analysis
For case-control association analysis, e.g. for C K D  and kidney 
stones, we utilized a standard likelihood ratio statistic, implement­
ed in the N E M O  software [32] to calculate two-sided P  values and 
odds ratios (O Rs) for each individual allele, assuming a 
multiplicative model for risk, i.e. that the risk of the two alleles 
carried by a person multiplies [36]. A llelic frequencies, rather 
than carrier frequencies, are presented for the markers and P  
values are given after adjustment for the relatedness of the 
subjects. W hen estimating genotype specific O R , genotype 
frequencies in the population were estimated assuming Hardy- 
W einberg equilibrium.
Results from multiple case-control groups were combined using 
a Mantel-Haenszel model [37] in which the groups were allowed 
to have different population frequencies for alleles, haplotypes and 
genotypes but were assumed to have common relative risks.
For the quantitative trait association analysis, e.g. for SC r and 
cystatin C, we utilized a robust linear regression based on an M  
estimator [38] as implemented in the rlm  function of the R  
software package [39]. An additive model for SN P  effects was 
assumed in all instances. A ll associations with quantitative traits 
were performed adjusting for age and sex.
Estimation and testing of interaction effects
Interaction effects were tested by assuming all main effects and 
lower order interaction effects were present under the null model
but not the interaction effect, resulting in a one degree of freedom 
model. For example, when testing for an interaction effect on SC r 
between age and the rs4293393-T allele count, the null model 
included as covariates age, sex and the rs4293393-T allele count. 
The alternative model included all these covariates as well as the 
product of the interaction of age and the rs4293393-T allele 
counts. Sim ilarly, when testing for the interaction between age, the 
number of comorbid conditions and the rs4293393-T allele count, 
the null model included as covariates age, sex, rs4293393-T allele 
count, the product of interaction of age and rs4293393-T allele 
count, the product of interaction of the number of comorbid 
conditions and rs4293393-T allele count, and the product of 
interaction of age and the number of comorbid conditions and the 
alternative model added the product of interaction of age, the 
rs4293393-T allele count and the number of comorbid conditions. 
In  the instances when an interaction effect was estimated, the main 
effect estimates and P  values shown were obtained from fitting the 
appropriate model without an interaction effect.
Correction for relatedness of the subjects and genomic 
control
Some of the individuals in the Icelandic patient and control 
groups are related to each other, causing the chi-square test 
statistic to have a mean > 1 and median >0.675. W e estimated the 
inflation factor for the genome-wide association by calculating the 
average of the 302,379 chi-square statistics, which was a method of 
genomic control [40] to adjust for both relatedness and potential 
population stratification. The inflation factor was estimated as 1.15 
for C K D  and 1.22 for SC r and all the results presented from 
association with these traits were adjusted based on these inflation 
factors.
Supporting Information
Figure S1 Q Q  plot of 2.5 m illion SN Ps in the genome-wide 
association scans for chronic kidney disease. The black dots 
represent the observed P  values and the blue ‘x’s represent the P  
values scaled down by an inflation factor estimated using genomic 
control (1.15). The diagonal red line represents where the dots are 
expected to fall under the null hypothesis of no association. The 
horizontal green line represents the threshold for genome-wide 
significance.
Found at: doi:10.1371/journal.pgen.1001039.s001 (0.69 M B  T IF )
Figure S2 Q Q  plot of 2.5 m illion SN Ps in the genome-wide 
association scans for serum creatinine. The black dots represent 
the observed P  values and the blue ‘x’s represent the P  values 
scaled down by an inflation factor estimated using genomic control 
(1.22). The diagonal red line represents where the dots are 
expected to fall under the null hypothesis of no association. The 
horizontal green line represents the threshold for genome-wide 
significance.
Found at: doi:10.1371/journal.pgen.1001039.s002 (0.69 M B  T IF )
Figure S3 The observed distribution of SC r measurements in 
Iceland and the Netherlands. The measurements from Iceland 
come from the Laboratory in M jodd and the C linical Biochem ­
istry Laboratory of Landspitali University Hospital (LU H ). The 
red line denotes the population median and the two dashed blue 
lines the 5%  and 95% quantiles. Measurements above 200 are 
lumped together for visualization purposes. The unit of measure­
ment is mmol/L.
Found at: doi:10.1371/journal.pgen.1001039.s003 (0.05 M B  EPS )
Table S1 Strongest SN P  associations (P<2?10—5) with C K D  
outside the UMOD region on chromosome 16p12.
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Found at: doi:10.1371/journal.pgen.1001039.s004 (0.05 M B  
D O C )
Table S2 Strongest SN P  associations (P< 10—6) with SC r outside 
the UMOD region on chromosome 16p12.
Found at: doi:10.1371/journal.pgen.1001039.s005 (0.10 M B  
D O C )
Table S3 Association of rs4293393-T with risk factors of kidney 
function decline in Icelandic case-control groups.
Found at: doi:10.1371/journal.pgen.1001039.s006 (0.03 M B  
D O C )
Table S4 Results of age-specific association for rs4293393-T and 
kidney stones using year of birth (YO B) as a proxy for age at onset. 
Found at: doi:10.1371/journal.pgen.1001039.s007 (0.03 M B  
D O C )
References
1. N ational K idney Foundation. (2002) K /D O Q I  clinical practice guidelines for 
chronic kidney disease: evaluation, classification, and  stratification. A m  J  K idney 
Dis 39: S1-266.
2. Sarnak M J, Levey AS, Schoolwerth A C, Coresh J ,  Culleton B, et al. (2003) 
K idney disease as a risk factor for developm ent o f cardiovascular disease: a 
statem ent from  the A m erican H eart Association Councils on K idney in 
Cardiovascular Disease, H igh Blood Pressure R esearch, Clinical Cardiology, 
and  Epidemiology and Prevention. C irculation 108: 2154-2169.
3. Lindem an R D , T obin  J D , Shock N W  (1984) Association between blood pressure 
and the rate o f decline in renal function with age. K idney In t 26: 861-868.
4. Fliser D , Franek E, Jo est M , Block S, M utschler E, e t al. (1997) R enal function in 
the elderly: im pact o f hypertension and  cardiac function. K idney In t 51: 
1196-1204.
5. Fliser D , R itz E (1998) Relationship between hypertension and renal function 
and its therapeutic implications in the elderly. Gerontology 44: 123-131.
6. Ribstein J ,  D u Cailar G , M im ran A  (2001) Glucose tolerance and age-associated 
decline in renal function of hypertensive patients. J  H ypertens 19: 2257-2264.
7. Kasiske BL (1987) Relationship between vascular disease and age-associated 
changes in the hum an kidney. K idney In t 31: 1153-1159.
8. Bleyer AJ, Shemanski LR , Burke GL, H ansen  K J, Appel R G  (2000) Tobacco, 
hypertension, and  vascular disease: risk factors for renal functional decline in an 
older population. K idney In t 57: 2072-2079.
9. V iktorsdottir O , Palsson R , A ndresdottir M B, Aspelund T , G udnason V , et al. 
(2005) Prevalence o f chronic kidney disease based on estim ated glomerular 
filtration rate and proteinuria in Icelandic adults. N ephrol D ial T ransplant 20: 
1799-1807.
10. Coresh J ,  Selvin E, Stevens LA, M anzi J ,  K usek JW , et al. (2007) Prevalence of 
chronic kidney disease in the U nited  States. JA M A  298: 2038-2047.
11. Lindem an R D , T obin  J ,  Shock N W  (1985) Longitudinal studies on the rate of 
decline in renal function with age. J  A m  G eriatr Soc 33: 278-285.
12. Smith D H , Gullion CM , Nichols G, K eith  DS, Brown JB  (2004) Cost of medical 
care for chronic kidney disease and com orbidity am ong enrollees in a large 
H M O  population. J  A m  Soc N ephrol 15: 1300-1306.
13. Fox CS, Y ang Q , Cupples LA, Guo CY , Larson M G , et al. (2004) Genomewide 
linkage analysis to serum creatinine, G FR , and creatinine clearance in a 
com munity-based population: the F ram ingham  H eart Study. J  Am Soc N ephrol 
15: 2457-2461.
14. K ottgen A, G lazer NL, D ehghan A, H w ang SJ, K atz R , et al. (2009) Multiple 
loci associated with indices of renal function and  chronic kidney disease. N at 
G enet 41: 712-717.
15. T h e  International H apM ap Consortium  (2005) A  haplotype map of the hum an 
genome. N ature 437: 1299-1320.
16. B achm ann S, K oeppen-H agem ann I, K riz W  (1985) U ltrastructural localization 
o f Tam m -H orsfall glycoprotein (THP) in ra t kidney as revealed by protein A- 
gold immunocytochemistry. Histochemistry 83: 531-538.
17. Peach RJ, D ay W A, Ellingsen PJ, M cG iven A R  (1988) U ltrastructural 
localization of Tam m -H orsfall protein in hum an kidney using im m unogold 
electron microscopy. H istochem J  20: 156-164.
18. Pook M A, Jerem iah  S, Scheinm an SJ, Povey S, Thakker R V  (1993) Localization 
o f the Tam m -H orsfall glycoprotein (uromodulin) gene to chrom osom e 16p12.3- 
16p13.11. A nn H um  G enet 57: 285-290.
19. Devuyst O , D ahan  K , Pirson Y (2005) Tam m -H orsfall protein or uromodulin: 
new ideas about an  old molecule. N ephrol D ial T ransplant 20: 1290-1294.
20. Leeker A, K reft B, Sandm ann J ,  Bates J ,  W asenauer G, et al. (1997) T am m ­
Horsfall protein inhibits binding of S- and  P-fimbriated Escherichia coli to 
hum an renal tubular epithelial cells. Exp N ephrol 5: 38-46.
Acknowledgments
The authors would like to thank all the individuals that participated in 
these studies and whose contribution made this work possible. We also 
thank our valued colleagues who contributed to the data collection and 
phenotypic characterization o f clinical samples, as well as genotyping and 
analysis o f the genome-wide association data.
Author Contributions
Conceived and designed the experiments: DFG H H  OSI V E LAK R P U T 
KS. Performed the experiments: OSI VE FdV FC H d M dH  LF T R  K K  
USB GIE LAK RP. Analyzed the data: D FG  H H  G T PS AK. Contributed 
reagents/m aterials/analysis tools: D FG  V E LF GIE. W rote the paper: 
DFG H H  O SI G T  VE RP U T KS.
21. Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate 
crystal aggregation by urine proteins. A m  J  Physiol 257: F99-106.
22. Saem ann M D , W eichhart T , Zeyda M , Staffler G, Schunn M , et al. (2005) 
Tam m -H orsfall glycoprotein links innate im m une cell activation w ith adaptive 
im munity via a Toll-like receptor-4-dependent mechanism. J  Clin Invest 115: 
468-475.
23. Yu C L , Tsai CY , Lin W M , Liao TS , C hen H L , et al. (1993) Tam m -H orsfall 
urinary glycoprotein enhances monokine release and  augm ents lymphocyte 
proliferation. Im m unopharm acology 26: 249-258.
24. B achm ann S, M utig K , Bates J ,  W elker P, Geist B, et al. (2005) Renal effects of 
Tam m -H orsfall protein (uromodulin) deficiency in mice. A m  J  Physiol Renal 
Physiol 288: F559-567.
25. Bates J M , Raffi H M , Prasadan K , M ascarenhas R , Laszik Z , et al. (2004) 
Tam m -H orsfall protein knockout mice are m ore prone to urinary tract infection: 
rapid com munication. K idney In t 65: 791-797.
26. M o L, H uang  HY, Zhu X H , Shapiro E, Hasty DL, et al. (2004) Tam m -H orsfall 
protein is a critical renal defense factor protecting against calcium oxalate crystal 
formation. K idney In t 66: 1159-1166.
27. R am poldi L, Caridi G, Santon D , Boaretto F, Bernascone I, et al. (2003) 
Allelism o f M C K D , FJH N  and G C K D  caused by im pairm ent o f urom odulin 
export dynamics. H um  M ol G enet 12: 3369-3384.
28. H a rt T C , G orry M C , H art PS, W oodard AS, Shihabi Z , et al. (2002) M utations 
o f the U M O D  gene are responsible for medullary cystic kidney disease 2 and 
familial juvenile hyperuricaem ic nephropathy. J  M ed G enet 39: 882-892.
29. Helgadottir A, Thorleifsson G, M anolescu A, G retarsdottir S, Blondal T , et al. 
(2007) A  com m on variant on chrom osom e 9p21 affects the risk o f m yocardial 
infarction. Science 316: 1491-1493.
30. G retarsdottir S, Thorleifsson G , M anolescu A, Styrkarsdottir U , Helgadottir A, 
e t al. (2008) Risk variants for atrial fibrillation on chrom osom e 4q25 associate 
with ischemic stroke. A nn N eurol 64: 402-409.
31. Steinthorsdottir V , Thorleifsson G , Reynisdottir I , Benediktsson R , Jonsdottir T , 
e t al. (2007) A  variant in CDKAL1 influences insulin response and risk of type 2 
diabetes. N at G enet 39: 770-775.
32. G retarsdottir S, Thorleifsson G , Reynisdottir S T , M anolescu A, Jonsdottir S, 
e t al. (2003) T he gene encoding phosphodiesterase 4D confers risk o f ischemic 
stroke. N at G enet 35: 131-138.
33. Wetzels J F , K iem eney LA, Swinkels DW , Willems H L, den Heijer M  (2007) 
Age- and gender-specific reference values o f estimated G FR in Caucasians: the 
Nijm egen Biomedical Study. K idney In t 72: 632-637.
34. M archini J ,  Howie B, Myers S, M cV ean G, Donnelly P (2007) A  new m ultipoint 
m ethod for genome-wide association studies by im putation of genotypes. N at 
G enet 39: 906-913.
35. K utyavin IV , Milesi D , Belousov Y, Podyminogin M , Vorobiev A, et al. (2006) A 
novel endonuclease IV  post-PCR genotyping system. Nucleic Acids Res 34: 
e128.
36. Rice J A  (1995) M athem atical Statistics and  D ata Analysis. BelmontCA: 
W adsw orth Inc.
37. M antel N , H aenszel W  (1959) Statistical aspects of the analysis o f data from 
retrospective studies o f disease. J  N atl Cancer Inst 22: 719-748.
38. H uber PJ (1981) Robust statistics. N ew  York: Wiley. pp 308.
39. T eam  R D C  (2009) R: A  Language for Statistical Com puting. V ienna, Austria: R  
Foundation for Statistical Computing.
40. Devlin B, R oeder K  (1999) G enomic control for association studies. Biometrics 
55: 997-1004.
PLoS Genetics | www.plosgenetics.org 9 July 2010 | Volume 6 | Issue 7 | e1001039
